Xbrane Biopharma AB (OSTO:XBRANE) E10: kr-115.69 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XBRANE Xbrane Biopharma AB OSTO:XBRANE
71 GF Score
Price kr9.18
GF Value kr5.97
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB E10?

Xbrane Biopharma AB OSTO:XBRANE -1.92% 71 E10 is kr-115.69 as of Jun. 2026. GuruFocus rates OSTO:XBRANE with a GF Score™ of 71/100 and a GF Value™ of kr5.97 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xbrane Biopharma AB's adjusted earnings per share data for the three months ended in Jun. 2026 was kr-0.550. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-115.69 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-27), Xbrane Biopharma AB's current stock price is kr9.18. Xbrane Biopharma AB's E10 for the quarter that ended in Jun. 2026 was kr-115.69. Xbrane Biopharma AB's Shiller PE Ratio of today is .


Xbrane Biopharma AB  (OSTO:XBRANE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xbrane Biopharma AB E10 Related Terms


Xbrane Biopharma AB E10 Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB E10 Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -175.98 -120.06

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -157.32 -124.41 -120.06 -117.63 -115.69

OSTO:XBRANE vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Shiller PE Ratio falls into.


OSTO:XBRANE
71GF Score
Xbrane Biopharma AB OSTO:XBRANE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.55/134.6100*134.6100
=-0.550

Current CPI (Jun. 2026) = 134.6100.

Xbrane Biopharma AB Quarterly Data

per share eps CPI Adj_EPS
201609 -26.197 101.138 -34.867
201612 -24.679 102.022 -32.562
201703 -24.585 102.022 -32.438
201706 -21.226 102.752 -27.807
201709 -20.555 103.279 -26.791
201712 -45.274 103.793 -58.716
201803 -20.830 103.962 -26.971
201806 -72.696 104.875 -93.308
201809 117.822 105.679 150.078
201812 -70.397 105.912 -89.472
201903 -73.042 105.886 -92.856
201906 -79.782 106.742 -100.612
201909 -37.269 107.214 -46.792
201912 -62.068 107.766 -77.529
202003 -47.614 106.563 -60.146
202006 -44.071 107.498 -55.186
202009 -42.371 107.635 -52.990
202012 -42.371 108.296 -52.667
202103 -32.735 108.360 -40.665
202106 -37.836 108.928 -46.757
202109 -25.933 110.338 -31.638
202112 -17.430 112.486 -20.858
202203 -20.406 114.825 -23.922
202206 -19.131 118.384 -21.753
202209 -23.665 122.296 -26.048
202212 -32.593 126.365 -34.720
202303 -1.417 127.042 -1.501
202306 -2.126 129.407 -2.211
202309 -39.369 130.224 -40.695
202312 -3.684 131.912 -3.759
202403 -37.500 132.205 -38.182
202406 -6.250 132.716 -6.339
202409 -3.750 132.304 -3.815
202412 -0.030 132.987 -0.030
202503 1.250 132.825 1.267
202506 0.110 133.699 0.111
202509 -2.500 133.480 -2.521
202512 -0.060 133.390 -0.061
202603 -0.620 133.560 -0.625
202606 -0.550 134.610 -0.550

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-115.69 mean?
Xbrane Biopharma AB (OSTO:XBRANE) has a E10 of kr-115.69 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's E10 too high?
Xbrane Biopharma AB's current E10 is kr-115.69. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's E10 compare to VRTX and REGN?
Xbrane Biopharma AB's E10 of kr-115.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current E10 is kr-115.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (OSTO:XBRANE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.97, compared to a current price of kr9.18 — trading 53.8% above its estimated fair value. The current E10 is kr-115.69. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Xbrane Biopharma AB (OSTO:XBRANE), the current E10 is kr-115.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr9.18 is trading 53.8% above its estimated GF Value™ of kr5.97. GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:XBRANE:

  • E10: kr-115.69
  • GF Value™: kr5.97 vs. price of kr9.18 (53.8% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xbrane Biopharma AB Business Description

Other Exchanges 7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for OSTO:XBRANE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.18
Price
kr5.97
GF Value